Moore Capital Management LP Acquires 81,438 Shares of RxSight, Inc. $RXST

Moore Capital Management LP raised its holdings in RxSight, Inc. (NASDAQ:RXST) by 116.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 151,500 shares of the company’s stock after acquiring an additional 81,438 shares during the period. Moore Capital Management LP’s holdings in RxSight were worth $730,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of RXST. Vitruvian Partners LLP acquired a new position in shares of RxSight in the 2nd quarter valued at approximately $1,344,129. Tocqueville Asset Management L.P. bought a new stake in RxSight during the 2nd quarter worth approximately $1,277,000. Walleye Capital LLC bought a new stake in RxSight during the 2nd quarter worth approximately $1,726,000. Healthcare of Ontario Pension Plan Trust Fund raised its holdings in RxSight by 761.0% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,131,400 shares of the company’s stock worth $6,969,000 after buying an additional 1,000,000 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new stake in RxSight during the 2nd quarter worth approximately $874,000. 78.78% of the stock is currently owned by institutional investors.

RxSight Stock Down 4.6%

RXST stock opened at $6.99 on Wednesday. The company has a market cap of $290.71 million, a price-to-earnings ratio of -6.19 and a beta of 1.16. RxSight, Inc. has a twelve month low of $4.48 and a twelve month high of $13.22. The business has a 50 day moving average price of $5.92 and a two-hundred day moving average price of $6.36.

RxSight (NASDAQ:RXST) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. The company had revenue of $33.74 million for the quarter, compared to analysts’ expectations of $32.55 million. RxSight had a negative return on equity of 17.35% and a negative net margin of 36.80%. On average, equities research analysts anticipate that RxSight, Inc. will post -1.01 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on RXST shares. Bank of America reduced their price target on shares of RxSight from $8.00 to $6.50 and set an “underperform” rating for the company in a report on Tuesday, July 7th. Stifel Nicolaus dropped their price objective on shares of RxSight from $8.00 to $7.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Wells Fargo & Company cut their price objective on shares of RxSight from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Thursday, May 7th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price on shares of RxSight in a report on Tuesday, July 7th. Finally, Wall Street Zen downgraded RxSight from a “hold” rating to a “sell” rating in a research note on Saturday. Two equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $8.37.

RxSight Profile

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.